Prostate cancer screening does not necessarily need to be performed every year. “If your PSA levels are very low, your ...

The use of a drug from Johnson & Johnson resulted in a lower spread of prostate cancer and reduced deaths, according to a study published on May 31. The drug Erleada—combined with therapy reducing ...

Pfizer (PFE) announced on Thursday that its cancer drug regimen, Talzenna plus Xtandi, met the primary endpoint in a Phase 3 trial for a new indication in prostate cancer. The Phase 3 TALAPRO-3 study ...

Candel Therapeutics is transitioning from a high-risk clinical-stage biotech to a late-stage oncology company with a BLA-directed lead asset. CAN-2409 has achieved positive Phase III results in ...

Many men prefer to skip regular screening or visiting their doctors just because of the false beliefs about the disease.

Johnson & Johnson's prostate cancer drug Erleada used with hormone-blocking therapy six months before and after prostate surgery improved the chances of eliminating the cancer and reduced the risk of ...

May 31 (Reuters) - Johnson & Johnson's prostate cancer drug Erleada used with hormone-blocking therapy six months before and after prostate surgery improved the chances of eliminating the cancer and ...